

(10) International Publication Number
WO 2016/043533 A1(43) International Publication Date
24 March 2016 (24.03.2016)

(51) International Patent Classification:

A61K 38/26 (2006.01) A61P 1/16 (2006.01)
A61K 47/48 (2006.01)Suji-gu, Yongin-si, Gyeonggi-do 16930 (KR). KWON, Se
Chang; 408-1804, 221, Seolleung-ro, Gangnam-gu, Seoul
06276 (KR).

(21) International Application Number:

PCT/KR2015/009753

(74) Agent: SON, Min; Hanol Intellectual Property&Law, STX
R&D Center, 6th Floor, 163, YangJaeCheon-ro, Gangnam-
gu, Seoul 06302 (KR).

(22) International Filing Date:

16 September 2015 (16.09.2015)

(81) Designated States (unless otherwise indicated, for every

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

10-2014-0122862

16 September 2014 (16.09.2014) KR

(71) Applicant: HANMI PHARM. CO., LTD. [KR/KR]; 214,
Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536
(KR).(72) Inventors: HWANG, Sang Youn; 154-601, 231,
Dongtanbanseok-ro, Hwaseong-si, Gyeonggi-do 18447
(KR). KIM, Jin Young; 5, Huseok-ro 46beon-gil,
Chuncheon-si, Gangwon-do 24387 (KR). KIM, Seung Su;
1501, 45, Seochojungang-ro, Seocho-gu, Seoul 06654
(KR). CHOI, In Young; 105-1801, 70, Yonggu-daero
2771beon-gil, Suji-gu, Yongin-si, Gyeonggi-do 16865
(KR). JUNG, Sung Youb; 709-104, 107, Manhyeon-ro,(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: USE OF A LONG ACTING GLP-1/GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-
ALCOHOLIC FATTY LIVER DISEASE

(57) Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves *in vivo* sustainability and stability.



Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))